Clinical Study

Rafael Panc003- A Phase III Multicenter Open-Label Randomized Trial To Evaluate Efficacy And Safety Of Folfirinox (Ffx) Versus Combination Of Cpi-613 With Modified Folfirinox (Mffx) In Patients With Metastatic Adenocarcinoma Of The Pancreas

Posted Date: Sep 4, 2020

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Oncology, Pancreatic Cancer
  • Type of Study: Drug

This is a prospective, multicenter, open label, randomized phase III study to evaluate efficacy and safety of FFX versus CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years. The primary outcome of this study is to determine Objective Response Rate.


To Be Eligible: Must Have Diagnosis Of Stage Iv Adenocarcinoma Of The Pancreas, Ecog 0-1, Age 18-75, Expected Survival >3 Months, No Prior Treatment For Study Cancer, No Hypersensitivity To Devimistat, Ffx Treatment Or Any Of Their Excipients, No Serious Medical Illness That Would Potentially Increase Patients' Risk For Toxicity


Pancreatic Cancer, Adenocarcinoma

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.